3ACTIVITIES
1ORGS REPRESENTED
5BILLS
Organizations represented
1Orgs whose LD-2 filings list Emily as an active lobbyist, sorted by activity volume.
Bills they file on
5Topics in Filings
134Policy topics Emily files on across all their LD-2 activities.
FY 2025 Appropriations×15
FY 2026 Appropriations×10
Bio COMPETES×5
House GOP RFI on Supply Chain×4
National Coverage Determination×3
Show all 134 topics (+129 more) ▾
Development and Procurement Issues×2
Risky Research Review Act×2
Biosecurity Infrastructure for Operational×2
Tropical Disease Priority Review Voucher×2
CICP×2
Interagency Patent Coordination and Improvement Act×2
Prescription Pricing for the People Act×2
Preserve Access to Affordable Generics and Biosimilars Act×2
Stop STALLING Act×2
Restrictions on Intellectual Property Rights×2
ORPHAN Cures Act×2
Pharmacy Benefit Manager Transparency Act×2
CMMI Authority×2
Development and Procurement×2
Funding for Strategic National Stockpile×2
MCM PRV×2
VICP×2
FY 2026 Appropriations Funding for National Institutes of Health×2
Advanced Research Projects Agency for Health×2
Monoclonal Antibody Coverage and Utilization×2
R&D Funding for Medical Countermeasures×2
American Innovation and R&D Competitiveness Act×2
American Innovation and Jobs Act×2
340B Drug Discount Program×1
Executive Order on Access to Affordable Life-Saving Medications×1
Program & Oversight×1
Accelerated Approval Artificial Intelligence×1
American Pandemic Preparedness Plan×1
MCM PRV Program Reauthorization×1
NDAA×1
Reasonable Pricing Clauses in BARDA Contracts×1
White House National Biodefense Strategy×1
WHO Pandemic Preparedness Accord Biosimilars×1
Biosimilar Copay×1
Interchangeability and Pharmacy Substitution×1
Reimbursement Cell & Gene Therapy×1
MINI Act×1
Climate Change×1
FY 2026 Appropriations Data Privacy×1
House GOP RFI on Data Privacy×1
Diversity & Inclusion×1
Decentralized Clinical Trials×1
Clinical Trial Diversity Drug Evaluation and Review×1
Promising Pathway Act×1
COVID-19 Lessons Learned×1
FDA Hiring Flexibility Drug Importation Drug Manufacturing×1
Quality & Distribution×1
Advanced Manufacturing×1
Drug Shortages×1
Safe, and Secure American Bioeconomy×1
Supply Chain Integrity and Traceability×1
Compounded Medicines×1
Patent Thickets×1
Maintaining Investments and New Innovation×1
COVID-19 Pricing Related Provisions×1
PBM Reform×1
Patient Cost-Sharing and Implementation×1
Strengthening Innovation in Medicare and Medicaid Act×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
Alternative Payment Arrangements for Gene Therapies×1
Average Manufacturer Price Calculations×1
Coverage of Accelerated Approval Products×1
Drug Benefit Design×1
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×1
Medicaid Drug Rebate Program Rule×1
Pricing and Rebates×1
Value-Based Purchasing×1
National Defense Authorization Act×1
SUPPORT Act×1
Non-Opioid Analgesics×1
Coverage and Reimbursement Orphan Drug Issues×1
Give Kids a Chance Act×1
Pediatric Priority Review Voucher Program×1
Orphan Drug Tax Credit Pandemic Preparedness×1
Drug Supply Chain Management×1
Supply Chain Issues×1
Temporarily Refundable R&D Credit×1
TRIPS Waiver×1
WHO Pandemic Preparedness Accord×1
Medical Countermeasures PRV Reauthorization×1
HELP Copays Act×1
Administration Rebate Rule×1
Lower Costs×1
More Cures Act×1
Medicare Part B Physician-Administered Products×1
Patient Cost-Sharing and Smoothing×1
Protected Classes×1
Support of Patient Premiums and Cost-Sharing Obligations×1
Value-based Contracting and Communications Vaccines and Infectious Diseases×1
Adult Immunization×1
Countermeasures Injury Compensation Program×1
Maternal Immunization×1
MCM Manufacturing & Capacity×1
MCM PRV Reauthorization×1
Vaccine and Antimicrobial Resistance Product Development and Incentives×1
Vaccine Injury Compensation Program×1
Vaccine Safety and Quality×1
Vaccine Safety net and Vaccine Infrastructure×1
Value of Vaccines and Vaccine Confidence×1
VICP Loopholes×1
Biodefense Research×1
Gene Editing×1
MCM PRV Program×1
HHS Reorganization×1
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×1
Funding for Biodefense/Biomedical/Emergency Preparedness Research×1
Womens Health Research Pandemic Preparedness×1
Incentives for Sustainable Aviation Fuels×1
Sustainable Aviation Fuels Tax Credit Capital Formation Incentives×1
American Innovation Act×1
Helping Startups Continue to Grow Act×1
Small Entity Update Act×1
Expanding Access to Capital Act×1
Equal Opportunity for All Investors Act×1
Infectious Disease Therapies Research and Innovation Act×1
Adjusting the well-known seasoned issues×1
Definition to allow for a larger financing round using×1
Net Operating Loss Advance Refunds×1
Orphan Drug Tax Credit×1
General Pandemic Preparedness Renewable Chemicals/Bio-based Products×1
Tax Relief for American Families and Workers Act×1
Expensing of R&D Expenditures×1
R&D Payroll Credit Vaccine Injury Compensation Program×1
Let Injured Americans Be Legally Empowered×1
Countermeasure Injury Compensation Fund Amendment Act×1
Vaccine Injury Compensation Modernization×1
Vaccine Access Improvement Act×1
Pulled from the org’s own LD-2 disclosures. See the source filings ↓
Issue mix
LDA general-issue codes weighted by activity count.
Health Issues1
Medical/Disease Research/Clinical Labs1
Taxation/Internal Revenue Code1